Cargando…
Short-Term Instantaneous Prophylaxis and Efficient Treatment Against SARS-CoV-2 in hACE2 Mice Conferred by an Intranasal Nanobody (Nb22)
Current COVID-19 vaccines need to take at least one month to complete inoculation and then become effective. Around 51% of the global population is still not fully vaccinated. Instantaneous protection is an unmet need among those who are not fully vaccinated. In addition, breakthrough infections cau...
Autores principales: | Wu, Xilin, Wang, Yaxing, Cheng, Lin, Ni, Fengfeng, Zhu, Linjing, Ma, Sen, Huang, Bilian, Ji, Mengmeng, Hu, Huimin, Li, Yuncheng, Xu, Shijie, Shi, Haixia, Zhang, Doudou, Liu, Linshuo, Nawaz, Waqas, Hu, Qinxue, Ye, Sheng, Liu, Yalan, Wu, Zhiwei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8967979/ https://www.ncbi.nlm.nih.gov/pubmed/35371009 http://dx.doi.org/10.3389/fimmu.2022.865401 |
Ejemplares similares
-
A potent bispecific nanobody protects hACE2 mice against SARS-CoV-2 infection via intranasal administration
por: Wu, Xilin, et al.
Publicado: (2021) -
AAV-mediated in vivo CAR gene therapy for targeting human T-cell leukemia
por: Nawaz, Waqas, et al.
Publicado: (2021) -
Potent Neutralizing Humanized Antibody With Topical Therapeutic Potential Against HPV18-Related Cervical Cancer
por: Huang, Bilian, et al.
Publicado: (2021) -
Advances in saRNA Vaccine Research against Emerging/Re-Emerging Viruses
por: Liu, Yalan, et al.
Publicado: (2023) -
Structure of Nanobody Nb23
por: Percipalle, Mathias, et al.
Publicado: (2021)